Abstract
Objective: Three prospective phase III clinical trials have shown a benefit of intraperitoneal (IP) chemotherapy as a front-line therapy in the treatment of ovarian cancer. However, little is known about the use of IP chemotherapy in recurrent ovarian cancer. The purpose of this descriptive study was to determine progression-free survival (PFS), overall survival (OS), completion rates, and frequency of complications in patients with epithelial ovarian cancer (EOC) treated with IP chemotherapy for recurrent disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
